about
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cellsRole of sorafenib in the treatment of advanced hepatocellular carcinoma: An updateHepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific regionChoosing the right cell line for renal cell cancer researchOncogenomics and the development of new cancer therapiesPreclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imagingThe study of a novel sorafenib derivative HLC-080 as an antitumor agentComparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical useRegorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical modelsTargeted therapy in melanoma.Angiogenesis inhibition in prostate cancer: current uses and future promises.Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phaA genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.Therapies in development for castrate-resistant prostate cancer.Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenibMultikinase inhibitors use in differentiated thyroid carcinoma.Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.Targeted therapy in hepatocellular carcinomaPhase I trial of sorafenib in patients with recurrent or progressive malignant glioma.Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosisJAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAFInhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growthTargeting paediatric acute lymphoblastic leukaemia: novel therapies currently in developmentTargeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.The discovery and development of sorafenib for the treatment of thyroid cancer.Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review.Sorafenib.A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.Mechanisms of drug inhibition of signalling molecules.Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer.Raf kinases: oncogenesis and drug discovery.
P2860
Q24602021-66AA52CA-F64E-4D8D-AB3B-7C5AFB17CCE9Q24619987-F663EE34-7E54-4E6F-A0C5-324312DD004BQ27026753-EB33320D-4B4B-4A80-987C-7FF2FB86B22AQ28073283-D1909A25-29DC-46C3-AA2D-4C5C68657389Q28263634-727ED9CE-674C-4BAD-90EC-DC3C8250FDF1Q28305337-D08DD68E-9E52-441F-A5DD-BCD8CA5F2D62Q28540521-1042A374-0F25-4414-830C-BEEB76BFB669Q28541231-0E9596DC-2FA7-46AF-80F2-474207476B30Q31131324-24B36BC5-B116-46E7-869C-4F42E6A39546Q33429478-FAEA087D-6415-4C9A-96BA-6FEE7D916904Q33430534-A6DAF2FA-035E-49B2-8C8F-5498DCEB8E0BQ33573107-78022B98-31E6-4767-B293-78D6FB8DA0B7Q33652297-AA76F810-6F43-4DE2-8E8C-2D0A5E839788Q33692392-7979E99C-A9E6-4163-8B36-C61464669836Q33900952-E76B076A-FD64-4942-AE3A-E8B1A49E9FEDQ34467228-BC97EC0F-F5D5-4555-A323-08D692B418E6Q34588402-7EDCAC80-E2CD-4FAA-A8D3-994D7F5A0691Q34625305-07FB1B8F-43AB-4B2C-A653-264B56392D48Q34660901-7D1B4A30-D3CC-47C3-89B1-7C4B8A2EEC66Q35080145-5B5D4583-AB5E-4E6D-B34C-CA5915C7CA55Q35166852-EBA5CC77-A6EA-4337-BFD0-00DA46F81853Q35207561-7DA6299E-A9CD-4FAE-865C-91C640D01A46Q35570274-06F2AE10-052F-4A5D-A294-997A8DDB1BB5Q35570953-C3D8F09E-B171-4856-9890-C67178DA729AQ35577914-87D167D4-21E3-426E-8020-68C52E02BBA4Q35635353-270C4647-15B9-4A6D-AC70-4EEF17223810Q35914464-6B86B6EF-22F2-4148-9BB2-74507FE43442Q35928707-C11E6CC2-9316-4408-A08F-ACAD98A3B031Q35967452-F57B38E6-04E2-4D84-842D-FAD172FACAE4Q36040272-3B17ED96-7A79-4E2F-9F7E-9C1B6EDBA161Q36180074-0E1A0D03-71CE-4835-B01F-D977F3226C73Q36241287-A681DDEE-9D7C-42D4-972A-76CF22D47620Q36261782-9E8C67BA-6FC3-4253-A715-F0E6E2774D38Q36263304-ACC48788-61C3-4352-94A3-548C51DCA2F2Q36370992-1B3F9217-1254-43E7-834D-DF71524AC1C1Q36407379-1CD49F07-F811-47EC-9D7D-3193A7D139C1Q36449359-B0A62DA7-AA89-4237-86BA-4CBAEA63226BQ36488752-0A886E27-4C78-4438-BA76-6B366D47C149Q36500021-A7C5F829-367C-4B3D-8457-B93A0319692CQ36559414-CB8D2872-8BAD-4808-B724-868F227598D2
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
BAY 43-9006: preclinical data.
@ast
BAY 43-9006: preclinical data.
@en
type
label
BAY 43-9006: preclinical data.
@ast
BAY 43-9006: preclinical data.
@en
prefLabel
BAY 43-9006: preclinical data.
@ast
BAY 43-9006: preclinical data.
@en
P356
P1476
BAY 43-9006: preclinical data.
@en
P2093
Du-Shieng Chien
Scott Wilhelm
P304
P356
10.2174/1381612023393026
P577
2002-01-01T00:00:00Z